» Articles » PMID: 36131296

Recapitulation of Pro-inflammatory Signature of Monocytes with ACVR1A Mutation Using FOP Patient-derived IPSCs

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2022 Sep 21
PMID 36131296
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by progressive heterotopic ossification (HO) in soft tissues due to a heterozygous mutation of the ACVR1A gene (FOP-ACVR1A), which erroneously transduces the BMP signal by Activin-A. Although inflammation is known to trigger HO in FOP, the role of FOP-ACVR1A on inflammatory cells remains to be elucidated.

Results: We generated immortalized monocytic cell lines from FOP-iPSCs (FOP-ML) and mutation rescued iPSCs (resFOP-ML). Cell morphology was evaluated during the monocyte induction and after immortalization. Fluorescence-activated cell sorting (FACS) was performed to evaluate the cell surface markers CD14 and CD16 on MLs. MLs were stimulated with lipopolysaccharide or Activin-A and the gene expression was evaluated by quantitative PCR and microarray analysis. Histological analysis was performed for HO tissue obtained from wild type mice and FOP-ACVR1A mice which conditionally express human mutant ACVR1A gene by doxycycline administration. Without any stimulation, FOP-ML showed the pro-inflammatory signature of CD16+ monocytes with an upregulation of INHBA gene, and treatment of resFOP-ML with Activin-A induced an expression profile mimicking that of FOP-ML at baseline. Treatment of FOP-ML with Activin-A further induced the inflammatory profile with an up-regulation of inflammation-associated genes, of which some, but not all, of which were suppressed by corticosteroid. Experiments using an inhibitor for TGFβ or BMP signal demonstrated that Activin-A-induced genes such as CD16 and CCL7, were regulated by both signals, indicating Activin-A transduced dual signals in FOP-ML. A comparison with resFOP-ML identified several down-regulated genes in FOP-ML including LYVE-1, which is known to suppress matrix-formation in vivo. The down-regulation of LYVE-1 in HO tissues was confirmed in FOP model mice, verifying the significance of the in vitro experiments.

Conclusion: These results indicate that FOP-ML faithfully recapitulated the phenotype of primary monocytes of FOP and the combination with resFOP-ML is a useful tool to investigate molecular events at the initial inflammation stage of HO in FOP.

Citing Articles

Intersections of Fibrodysplasia Ossificans Progressiva and Traumatic Heterotopic Ossification.

Juan C, Bancroft A, Choi J, Nunez J, Pagani C, Lin Y Biomolecules. 2024; 14(3).

PMID: 38540768 PMC: 10968060. DOI: 10.3390/biom14030349.


Oxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva.

Sun L, Jin Y, Nishio M, Watanabe M, Kamakura T, Nagata S Life Sci Alliance. 2024; 7(5).

PMID: 38365425 PMC: 10875110. DOI: 10.26508/lsa.202302219.


Human iPSCs as Model Systems for BMP-Related Rare Diseases.

Sanchez-Duffhues G, Hiepen C Cells. 2023; 12(17).

PMID: 37681932 PMC: 10487005. DOI: 10.3390/cells12172200.


Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future Directions.

Shaikh U, Khan A, Kumari P, Ishfaq A, Ekhator C, Yousuf P Cureus. 2023; 15(7):e42614.

PMID: 37521595 PMC: 10378717. DOI: 10.7759/cureus.42614.

References
1.
Yokoyama K, Ikeya M, Umeda K, Oda H, Nodomi S, Nasu A . Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP/protein kinase A/CREB pathway. Arthritis Rheumatol. 2014; 67(1):302-14. DOI: 10.1002/art.38912. View

2.
Phillips D, de Kretser D, Hedger M . Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev. 2009; 20(2):153-64. DOI: 10.1016/j.cytogfr.2009.02.007. View

3.
Shahbazian D, Parsyan A, Petroulakis E, Hershey J, Sonenberg N . eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle. 2010; 9(20):4106-9. PMC: 3055195. DOI: 10.4161/cc.9.20.13630. View

4.
Shore E, Kaplan F . Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone. 2008; 43(3):427-33. PMC: 2601573. DOI: 10.1016/j.bone.2008.05.013. View

5.
Terry R, Miller S . Molecular control of monocyte development. Cell Immunol. 2014; 291(1-2):16-21. PMC: 4162862. DOI: 10.1016/j.cellimm.2014.02.008. View